Cochrane · systematic review · CD008842
Immunosuppressive T‐cell antibody induction for heart transplant recipients
Penninga, L, Møller, CH, Gustafsson, F, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
30
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 30 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antibody induction for heart transplant recipients
Population: heart transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest | RR 1.53 [0.85, 2.76] | 5 studies · 606 participants | Low Downgraded: risk of bias |
Acute rejection Acute rejection grade 3A or more verified by biopsy | RR 0.73 [0.46, 1.17] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Infection Number of participants diagnosed with infection | RR 0.99 [0.79, 1.24] | 3 studies · 545 participants | Low Downgraded: risk of bias |
Cytomegalovirus infection Number of patients diagnosed with CMV infection | RR 0.86 [0.63, 1.19] | 5 studies · 606 participants | Low Downgraded: risk of bias |
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD | RR 0.74 [0.14, 3.82] | 5 studies · 606 participants | Low Downgraded: risk of bias |
Cancer Number of participants diagnosed with cancer | RR 1.01 [0.45, 2.28] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Interleukin‐2 RA compared to no induction for heart transplant recipients
Population: heart transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest Interleukin‐2 RA vs no induction | RR 1.53 [0.85, 2.76] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Acute rejection Acute rejection grade 3A or more verified by biopsy Interleukin‐2 RA vs no induction | RR 0.73 [0.46, 1.17] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Infection Number of participants diagnosed with infection Interleukin‐2 RA vs no induction | RR 0.99 [0.79, 1.24] | 3 studies · 545 participants | Low Downgraded: risk of bias |
Cytomegalovirus infection Number of participants diagnosed with CMV infection Interleukin‐2 RA vs no induction | RR 0.86 [0.62, 1.19] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD Interleukin‐2 RA vs no induction | RR 0.61 [0.08, 4.92] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Cancer Number of participants diagnosed with cancer Interleukin‐2 RA vs no induction | RR 1.01 [0.45, 2.28] | 4 studies · 576 participants | Low Downgraded: risk of bias |
Interleukin‐2 RA induction compared to monoclonal antibody induction for heart transplant recipients
Population: heart transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest Interleukin‐2 RA induction vs monoclonal antibody induction | RR 0.8 [0.19, 3.41] | 2 studies · 159 participants | Low Downgraded: risk of bias |
Acute rejection Acute rejection grade 3A or more verified by biopsy Interleukin‐2 RA induction vs monoclonal antibody induction | RR 0.97 [0.77, 1.23] | 2 studies · 159 participants | Low Downgraded: risk of bias |
Infection Number of participants diagnosed with infection Interleukin‐2 RA induction vs monoclonal antibody induction | RR 0.91 [0.54, 1.53] | 2 studies · 159 participants | Low Downgraded: risk of bias |
Cytomegalovirus infection Number of participants diagnosed with CMV infection Interleukin‐2 RA induction vs monoclonal antibody induction | RR 0.94 [0.43, 2.06] | 2 studies · 159 participants | Low Downgraded: risk of bias |
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD Interleukin‐2 RA induction vs monoclonal antibody induction | RR 0.31 [0.01, 7.38] | 2 studies · 159 participants | Low Downgraded: risk of bias |
Cancer Number of participants diagnosed with cancer Interleukin‐2 RA induction vs monoclonal antibody induction | RR 0.84 [0.4, 1.77] | 2 studies · 159 participants | Low Downgraded: risk of bias |
Interleukin‐2 RA versus polyclonal antibody induction for heart transplant recipients
Population: heart transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest Interleukin‐2 RA vs polyclonal antibody induction | RR 1.1 [0.65, 1.88] | 4 studies · 185 participants | Low Downgraded: risk of bias |
Acute rejection Acute rejection grade 3A or more verified by biopsy Interleukin‐2 RA vs polyclonal antibody induction | RR 2.43 [1.01, 5.86] | 4 studies · 185 participants | Low Downgraded: risk of bias |
Infection Number of participants diagnosed with infection Interleukin‐2 RA vs polyclonal antibody induction | RR 0.85 [0.71, 1.03] | 3 studies · 155 participants | Low Downgraded: risk of bias |
Cytomegalovirus infection Number of participants diagnosed with CMV infection Interleukin‐2 RA vs polyclonal antibody induction | RR 0.97 [0.53, 1.75] | 4 studies · 185 participants | Low Downgraded: risk of bias |
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD Interleukin‐2 RA vs polyclonal antibody induction | no estimate extracted | 4 studies · 185 participants | Low Downgraded: risk of bias |
Cancer Number of participants diagnosed with cancer Interleukin‐2 RA vs polyclonal antibody induction | RR 9 [0.52, 156.91] | 4 studies · 185 participants | Low Downgraded: risk of bias |
Monoclonal antibody compared to polyclonal antibody for heart transplant recipients
Population: heart transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest Monoclonal antibody vs polyclonal antibody | RR 1 [0.9, 1.1] | 7 studies · 315 participants | Low Downgraded: risk of bias |
Acute rejection Acute rejection grade 3A or more verified by biopsy Monoclonal antibody vs polyclonal antibody | RR 0.96 [0.67, 1.37] | 3 studies · 146 participants | Low Downgraded: risk of bias |
Infection Number of participants diagnosed with infection Monoclonal antibody vs polyclonal antibody | RR 1.12 [0.91, 1.39] | 5 studies · 214 participants | Low Downgraded: risk of bias |
Cytomegalovirus infection Number of participants diagnosed with CMV infection Monoclonal antibody vs polyclonal antibody | RR 1.32 [0.77, 2.28] | 4 studies · 201 participants | Low Downgraded: risk of bias |
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD Monoclonal antibody vs polyclonal antibody | RR 3.84 [0.45, 32.96] | 4 studies · 157 participants | Low Downgraded: risk of bias |
Cancer Number of participants diagnosed with cancer Monoclonal antibody vs polyclonal antibody | RR 2.19 [0.51, 9.43] | 4 studies · 157 participants | Low Downgraded: risk of bias |